F-18 Fluoroethyltyrosine (FET) for Relapse
Phase-Based Progress Estimates
Effectiveness
Safety
Relapse+9 More
F-18 Fluoroethyltyrosine (FET) - DrugEligibility
Any Age
All Sexes
What conditions do you have?
Select
Eligibility
Any Age
All Sexes
What conditions do you have?
Select
Study Summary
This trial uses an imaging agent to see if it can help detect tumors in participants who have had them come back.
Eligible Conditions
- Relapse
- Glioma
- Low Grade Glioma (LGG)
- Neoplasms, Intracranial
- Glioblastoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 2 Secondary · Reporting Duration: Up to 6 months
Day 1
Misclassification rate for either having recurrent disease or not having recurrent disease for patients previously treated for glial and metastatic disease (Population 1)
Misclassification rate for either high grade or low grade in patients with suspected neoplasms (Population 2)
Up to 6 months
Binary characterization of follow-up imaging as positive/negative for tumor recurrence
Misclassification rate for FET PET in the evaluation of recurrent low-grade gliomas (Population 1)
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Trial Design
1 Treatment Group
Diagnostic FET PET
1 of 1
Experimental Treatment
199 Total Participants · 1 Treatment Group
Primary Treatment: F-18 Fluoroethyltyrosine (FET) · No Placebo Group · Phase 2
Diagnostic FET PETExperimental Group · 2 Interventions: F-18 Fluoroethyltyrosine (FET), Positron Emission Tomography (PET) · Intervention Types: Drug, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography (PET)
2019
Completed Phase 3
~1270
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 months
Who is running the clinical trial?
Thomas HopeLead Sponsor
8 Previous Clinical Trials
1,420 Total Patients Enrolled
Thomas A Hope, MDPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
330 Total Patients Enrolled
Eligibility Criteria
Age Any Age · All Participants · 6 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:Presence or suspicion of intracranial neoplasm in two populations.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments